Targeted delivery of mutant Raf kinase to neovessels causes tumor regression

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 67, Issue , 2002, Pages 285-291

  Hood, J D ^a   Cheresh, D A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CELL RECEPTOR; CELL SURFACE MARKER; FOCAL ADHESION KINASE; GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; INTEGRIN; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MUTANT PROTEIN; NANOPARTICLE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN CDC42; PROTEIN KINASE C; PROTEIN KINASE P60; PROTEIN P21; RAC PROTEIN; RAF PROTEIN; RAS PROTEIN; RHO KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VITRONECTIN; VITRONECTIN RECEPTOR; GROWTH FACTOR;

ANGIOGENESIS; APOPTOSIS; CELL ADHESION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONFERENCE PAPER; COVALENT BOND; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; HUMAN; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR REGRESSION; TUMOR VASCULARIZATION; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD VESSEL; GENE MUTATION; GENETIC CODE; MOLECULARLY TARGETED THERAPY;

EID: 0038124364     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2002.67.285     Document Type: Conference Paper

References (47)

1. Alon T., Hemo I., Itin A., Pe'er J., Stone J., and Keshet E. 1995. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1: 1024.
2. Aplin A.E., Howe A., Alahari S.K., and Juliano R.L. 1998. Signal transduction and signal modulation by cell adhesion receptors: The role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol. Rev. 50: 197.
3. Arap W., Pasqualini R., and Ruoslahti E. 1998. Chemotherapy targeted to tumor vasculature. Curr. Opin. Oncol. 10: 560.
4. Berinstein A., Roivainen M., Hovi T., Mason P.W., and Baxt B. 1995. Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J. Virol. 69: 2664.
5. Blezinger P., Wang J., Gondo M., Quezada A., Mehrens D., French M., Singhal A., Sullivan S., Rolland A., Ralston R., and Min W. 1999. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol. 17: 343.
6. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., and Cheresh D.A. 1994. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157.
7. Chaudhary A., King W.G., Mattaliano M.D., Frost J.A., Diaz B., Morrison D.K., Cobb M.H., Marshall M.S., and Brugge J.S. 2000. Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338. Curr. Biol. 10: 551.
8. del Pozo M.A., Price L.S., Alderson N.B., Ren X.D., and Schwartz M.A. 2000. Adhesion to the extracellular matrix regulates the coupling of the small GTPase Rac to its effector PAK. EMBO J. 19: 2008.
9. Eliceiri B.P. 2001. Integrin and growth factor receptor crosstalk. Circ. Res. 89: 1104.
10. Eliceiri B.P. and Cheresh D.A. 2001. Adhesion events in angiogenesis. Curr. Opin. Cell Biol. 13: 563.
11. Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J., and Cheresh D.A. 1999. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell 4: 915.
12. Fabian J.R., Daar I.O., and Morrison D.K. 1993. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol. Cell. Biol. 13: 7170.
13. Folkman J. 2001. Angiogenesis-dependent diseases. Semin. Oncol. 28: 536.
14. Friedlander M., Brooks P.C., Shaffer R.W., Kincaid C.M., Varner J.A., and Cheresh D.A. 1995. Definition of two angiogenic pathways by distinct alpha v integrins. Science 270: 1500.
15. Giancotti F.G. and Ruoslahti E. 1999. Integrin signaling. Science 285: 1028.
16. Guerrero C.A., Mendez E., Zarate S., Isa P., Lopez S., and Arias C.F. 2000. Integrin alpha(v)beta(3) mediates rotavirus cell entry. Proc. Natl. Acad. Sci. 97: 14644.
17. Gutheil J.C., Campbell T.N., Pierce P.R., Watkin J.D., Huse W.D., Bodkin D.J., and Cheresh D.A. 2000. Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin αvβ3. Clin. Cancer Res. 6: 3056.
18. Heidecker G., Huleihel M., Cleveland J.L., Kolch W., Beck T.W., Lloyd P., Pawson T., and Rapp U.R. 1990. Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol. Cell. Biol. 10: 2503.
19. Hood J.D. and Cheresh D.A. 2002. Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2: 91.
20. Hood J., Bednarski M.D., Frausto R., Guccione S., Reisfeld R.A., Xiang R., and Cheresh D.A. 2002. Tumor regression by targeted gene delivery to the neovasculature. Science 296: 2404.
21. Huser M., Luckett J., Chiloeches A., Mercer K., Iwobi M., Giblett S., Sun X.M., Brown J., Marais R., and Pritchard C. 2001. MEK kinase activity is not necessary for Raf-1 function. EMBO J. 20: 1940.
22. Kim S., Bell K., Mousa S.A., and Varner J.A. 2000. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am. J. Pathol. 156: 1345.
23. King A.J., Sun H., Diaz B., Barnard D., Miao W., Bagrodia S., and Marshall M.S. 1998. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature 396: 180.
24. Kiosses W.B., Hood J., Yang S., Gerritsen M.E., Cheresh D.A., Alderson N., and Schwartz M.A. 2002. A dominant-negative p65 PAK peptide inhibits angiogenesis. Circ. Res. 90: 697.
25. Kolch W. 2000. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 351: 289.
26. Kumar C.C., Malkowski M., Yin Z., Tanghetti E., Yaremko B., Nechuta T., Varner J., Liu M., Smith E.M., Neustadt B., Presta M., and Armstrong L. 2001. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 61: 2232.
27. Langmuir V.K., Cobleigh M.A., Herbst R.S., Holmgren E., Hurwitz H., Kabbinava F., Miller K., and Novotny W. 2002. Successful long-term therapy with bevacizumab (Avastin™) in solid tumors. In Abstracts from the 38th Annual Meeting of the American Society of Clinical Oncology (Orlando, Florida), p. 32.
28. Liu Y., Mounkes L.C., Liggitt H.D., Brown C.S., Solodin I., Heath T.D., and Debs R.J. 1997. Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat. Biotechnol. 15: 167.
29. Losordo D.W., Vale P.R., Symes J.F., Dunnington C.H., Esakof D.D., Maysky M., Ashare A.B., Lathi K., and Isner J.M. 1998. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98: 2800.
30. Marshall C.J. 1995. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179.
31. Murakami M.S. and Morrison D.K. 2001. Raf-1 without MEK? Sci. STKE 2001: PE30.
32. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., and Folkman J. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277.
33. Pearson G., Robinson F., Beers Gibson T., Xu B.E., Karandikar M., Berman K., and Cobb M.H. 2001. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr. Rev. 22: 153.
34. Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C., Pihlajaniemi T., Alitalo K., and Vuori K. 2001. Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. 98: 1024.
35. Renshaw M.W., Ren X.D., and Schwartz M.A. 1997. Growth factor activation of MAP kinase requires cell adhesion. EMBO J. 16: 5592.
36. Ridley A. 2000. Rho GTPases. Integrating integrin signaling. J. Cell Biol. 150: F107.
37. Schlessinger J. 2000. New roles for Src kinases in control of cell survival and angiogenesis. Cell 100: 293.
38. Schwartz M.A. and Ginsberg M.H. 2002. Networks and crosstalk: Integrin signalling spreads. Nat. Cell Biol. 4: E65.
39. Senger D.R., Ledbetter S.R., Claffey K.P., Papadopoulos-Sergiou A., Peruzzi C.A., and Detmar M. 1996. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am. J. Pathol. 149: 293.
40. Sipkins D.A., Cheresh D.A., Kazemi M.R., Nevin L.M., Bednarski M.D., and Li K.C. 1998. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat. Med. 4: 623.
41. Stupack D.G., Puente X.S., Boutsaboualoy S., Storgard C.M., and Cheresh D.A. 2001. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J. Cell Biol. 155: 459.
42. Wang H.G., Rapp U.R., and Reed J.C. 1996. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87: 629.
43. Wang Y. and Becker D. 1997. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat. Med. 3: 887.
44. Wickham T.J., Mathias P., Cheresh D.A., and Nemerow G.R. 1993. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309.
45. Wojnowski L., Zimmer A.M., Beck T.W., Hahn H., Bernal R., Rapp U.R., and Zimmer A. 1997. Endothelial apoptosis in Braf-deficient mice. Nat. Genet. 16: 293.
46. Xiang R., Lode H.N., Dolman C.S., Dreier T., Varki N.M., Qian X., Lo K.M., Lan Y., Super M., Gillies S.D., and Reisfeld R.A. 1997. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res. 57: 4948.
47. Yancopoulos G.D., Klagsbrun M., and Folkman J. 1998. Vasculogenesis, angiogenesis, and growth factors: Ephrins enter the fray at the border. Cell 93: 661.